Doubts Over China's First Alzheimer's Drug Resurface Amid Research Miscount Allegation
Speed Over Quality?
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
